CD8A and neoplasm: Intriguingly, upon analyzing the composition of CD8 TILs, rhIL-7-hyFc treatment led to a significantly higher increase in PD-1+ tumor-reactive CD8 TILs in STL mice compared to sham mice (Figure 4C).